Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 16/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL739874 | 0.91 | HTR6 (0.58) | HTR6DRD2DRD3HTR2AHTR2C | |
| Trifluoroacetic Acid SCHEMBL743223 | 0.88 | HTR6 (0.53) | HTR6LMNASMN1; SMN2TPSAB1DRD2 | |
| Trifluoroacetic Acid SCHEMBL742626 | 0.87 | HTR6 (0.46) | HTR6TPSAB1DRD2DRD3 | |
| SCHEMBL742305 | 0.82 | HTR6 (0.54) | HTR6DRD2DRD3MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL742236 | 0.81 | HTR6 (0.53) | HTR6DRD2DRD3MEN1KMT2A | |
| Trifluoroacetic Acid SCHEMBL743477 | 0.81 | HTR6 (0.51) | HTR6TPSAB1HTR2C | |
| Trifluoroacetic Acid SCHEMBL742123 | 0.81 | HTR6 (0.42) | HTR6LMNATPSAB1HTR2C | |
| Trifluoroacetic Acid SCHEMBL742634 | 0.81 | HTR6 (0.45) | HTR6TPSAB1HTR2C | |
| SCHEMBL742406 | 0.81 | KMT2A (0.44) | HTR6LMNAMEN1KMT2AHTR2C | |
| SCHEMBL742701 | 0.78 | HTR6 (0.62) | HTR6LMNASMN1; SMN2DRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138333-B2 | Sulfonyl-indole derivatives | PROXIMAGEN LIMITED (GB) | 2012-03-20 | — | — | US | disclosed |
| EP-2134714-A1 | TRICYCLIC ISOQUINOLINE DERIVATIVES FOR TREATMENT OF OBESITY | Biovitrum AB (publ) (SE) | 2009-12-23 | — | — | EP | disclosed |
| US-20080293694-A1 | New compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-11-27 | — | — | US | disclosed |
| WO-2008110598-A1 | TRICYCLIC ISOQUINOLINE DERIVATIVES FOR TREATMENT OF OBESITY | BIOVITRUM AB (PUBL) (SE) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293694-A1 | New compounds | HTR6, HTR1A, HTR1B | HTR6 1/4885LMNA 3634/4885SMN1; SMN2 1945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.